| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 06/07/2022 | 0.3% | HC Wainwright & Co. | → $10 | Downgrades | Buy → Neutral |
| 05/06/2022 | -89.97% | Cantor Fitzgerald | $5 → $1 | Downgrades | Overweight → Neutral |
| 03/11/2022 | -74.92% | HC Wainwright & Co. | $3 → $2.5 | Maintains | Buy |
| 11/12/2021 | -69.91% | HC Wainwright & Co. | $4 → $3 | Maintains | Buy |
| 08/07/2020 | -87.96% | Jefferies | $1.25 → $1.2 | Downgrades | Hold → Underperform |
| 05/19/2020 | — | JP Morgan | Downgrades | Overweight → Neutral | |
| 05/07/2020 | -49.85% | HC Wainwright & Co. | $6 → $5 | Reiterates | → Buy |
| 04/16/2020 | 50.45% | Stifel | $14 → $15 | Maintains | Buy |
| 02/21/2020 | -39.82% | HC Wainwright & Co. | $7 → $6 | Maintains | Buy |
| 08/14/2018 | 170.81% | Cantor Fitzgerald | $26 → $27 | Maintains | Overweight |
| 06/15/2018 | 10.33% | JP Morgan | → $11 | Initiates Coverage On | → Overweight |
| 09/08/2017 | -39.82% | Morgan Stanley | → $6 | Initiates Coverage On | → Equal-Weight |
| 07/21/2017 | 0.3% | Deutsche Bank | → $10 | Initiates Coverage On | → Buy |
| 07/11/2017 | — | Oppenheimer | Upgrades | Perform → Outperform |
TherapeuticsMD Questions & Answers
The latest price target for TherapeuticsMD (NASDAQ: TXMD) was reported by HC Wainwright & Co. on June 7, 2022. The analyst firm set a price target for $10.00 expecting TXMD to rise to within 12 months (a possible 0.30% upside). 4 analyst firms have reported ratings in the last year.
The latest analyst rating for TherapeuticsMD (NASDAQ: TXMD) was provided by HC Wainwright & Co., and TherapeuticsMD downgraded their neutral rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TherapeuticsMD, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TherapeuticsMD was filed on June 7, 2022 so you should expect the next rating to be made available sometime around June 7, 2023.
While ratings are subjective and will change, the latest TherapeuticsMD (TXMD) rating was a downgraded with a price target of $0.00 to $10.00. The current price TherapeuticsMD (TXMD) is trading at is $9.97, which is within the analyst's predicted range.